In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates
1
Department of Pharmacy, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157, USA
2
Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
3
Department of Internal Medicine, Section on Infectious Diseases, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Antibiotics 2023, 12(6), 953; https://doi.org/10.3390/antibiotics12060953
Submission received: 12 April 2023
/
Revised: 11 May 2023
/
Accepted: 20 May 2023
/
Published: 24 May 2023
(This article belongs to the Special Issue Urinary Tract Infections and Antibiotic Intervention)
Abstract
:Limited oral antibiotic options exist for urinary tract infections (UTI) caused by ESBL-producing Enterobacterales. The aim of the study was to evaluate in vitro activity of omadacycline and comparator antibiotics against clinical ESBL-producing and non-ESBL-producing E. coli and K. pneumoniae urinary isolates. 102 isolates each of E. coli and K. pneumoniae were collected from clinical urine specimens in 2019. By design, an equal number of each species were included that tested positive and negative for ESBL production. Omadacycline MICs were determined using gradient test strips and compared to MICs of comparator antibiotics as determined by an automated broth microdilution system. Isolates were considered susceptible to omadacycline if the MIC was ≤4 µg/mL for each species. 54.9% of all ESBL-producing isolates were susceptible to omadacycline, but better susceptibility was observed for ESBL-producing E. coli (74.5%). Omadacycline MICs were 2–4 fold lower for E. coli and K. pneumoniae strains not producing ESBL. The omadacycline MIC 50 and 90 values were 4 and 16 µg/mL, respectively, for all isolates studied. 74.5% of all isolates were considered susceptible to omadacycline. MICs were generally lower for E. coli strains with MIC 50 and 90 values of 4 and 8 µg/mL, respectively (87.3% susceptible), compared with K. pneumoniae. Overall, the most active agents were omadacycline and nitrofurantoin, while other comparator antibiotics were less active. Omadacycline represents a promising oral antibiotic for treating UTI caused by ESBL-producing E. coli, particularly when resistance limits other oral options. Prospective, controlled clinical trials are needed to validate these in vitro results.
1. Introduction
Urinary tract infection (UTI) is one of the most common causes of bacterial infection requiring antibiotic therapy [1,2]. Despite the fact that many different microorganisms have been identified as causative pathogens in UTIs, Escherichia coli and Klebsiella pneumoniae are among those most frequently implicated [3]. UTI recurrence rates are often high and antimicrobial resistance has been increasing against currently available oral antibiotics [4]. Furthermore, extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales have been increasingly identified [5,6]. UTI caused by ESBL-producing Enterobacterales often leave medical providers with a limited number of effective treatment options, especially orally administered antibiotics [7,8]. The World Health Organization has published a list of target organisms with priority to help guide the development of new antibiotics [9]. In this list, third generation cephalosporin-resistant Enterobacterales, e.g., ESBL-producers, are considered a critical priority.
Omadacycline is the first novel agent in the class of aminomethylcyclines. Omadacycline has been shown to have in vitro activity against Enterobacterales isolates resistant to traditional tetracycline antibiotics [10]. Oral and intravenous (IV) omadacycline is approved by the US Food and Drug Administration (FDA) for acute bacterial skin and skin structure infections and community acquired bacterial pneumonia in adults. Its mechanism of action is similar to other tetracycline antibiotics, inhibiting protein synthesis via 16S rRNA component of the 30S subunit of the bacterial ribosome. However, omadacycline has a two-fold higher binding affinity for the 30S ribosome than tetracycline [11]. Although the documented spectrum of in vitro activity for omadacycline includes ESBL-producing Enterobacterales, this agent has not been FDA-approved for treatment of UTI, the most common infection caused by ESBL-producing Enterobacterales [7]. The aim of the study was to evaluate in vitro activity of omadacycline and comparator antibiotics against clinical ESBL-producing and non-ESBL producing E coli and Klebsiella pneumoniae isolates recovered from urine specimens.
2. Materials and Methods
A total of 102 E. coli and 102 K. pneumoniae non-duplicate strains were isolated consecutively from clinical urine specimens of adult patients submitted to the clinical microbiology lab of Atrium Health Wake Forest Baptist between March and October 2019. By design, an equal number of each species were included that tested positive and negative for ESBL production as determined by MicroScan WalkAway system (Beckman Coulter West Sacramento, CA, USA). The samples were processed for quantitative urine culture by inoculating a 10 µL urine sample onto 5% sheep blood and MacConkey agar plates and incubated at 35 °C for 18–24 h according to standard protocols. Organisms were identified to the species level by matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (Bruker Daltonics, Billerica, MA, USA).
All isolates were tested in triplicate for omadacycline susceptibility and the minimum inhibitory concentrations (MIC) were determined using MIC gradient test strips (Liofilchem, Inc., Waltham, MA, USA) according to the manufacturer’s instructions. In addition, five oral antibiotics commonly prescribed for the treatment of UTIs (tetracycline, amoxicillin-clavulanate, trimethoprim-sulfamethoxazole, nitrofurantoin, and ciprofloxacin) were tested by broth microdilution using the MicroScan WalkAway system. MIC results for these comparator agents were interpreted in concordance with Clinical and Laboratory Standards Institute (CLSI) M100 guidelines [12]. In the absence of omadacycline CLSI breakpoints for E. coli, FDA breakpoints of K. pneumoniae were applied [13]. For the purpose of this study, all isolates were considered susceptible to omadacycline if the MIC was ≤4 µg/mL. MIC 50 and 90 values were calculated for categories of isolates according to species and ESBL-production. Chi Square test was performed to compare proportions within and between categories, e.g., omadacycline vs. comparator antibiotics, E. coli vs. K. pneumoniae. This study was approved by the Institutional Review Board of Wake Forest University Health Sciences, including waiver of the requirement to obtain informed consent.
3. Results
Susceptibility results, including MIC 50, MIC 90, MIC range, modal MIC, and percent susceptible, are summarized in Table 1. For all ESBL-producing isolates, the omadacycline MIC 50/90 was 4/>32 with 54.9% susceptible, which was significantly lower than non-ESBL-producing isolates (91.2%, p < 0.001). Omadacycline was second only to nitrofurantoin (71.6% susceptible) among ESBL-producing isolates (p = 0.014). Tetracycline, ciprofloxacin, and trimethoprim-sulfamethoxazole performed poorly against ESBL-producing isolates as the percent susceptible for these was no greater than 26.5% (p < 0.001 vs omadacycline). Omadacycline was generally more active (about one dilution lower MIC) against E. coli than K. pneumoniae (87.3% vs. 61.8% susceptible, p < 0.001). 100% of non-ESBL-producing E. coli were susceptible to omadacycline. The omadacycline MIC 50/90 values were 2/4 and 4/16 µg/mL for non-ESBL-producing and ESBL-producing E. coli, respectively, and 4/8 and 8/>32 for non-ESBL-producing and ESBL-producing K. pneumoniae, respectively. For all isolates studied (N = 204), the omadacycline MIC 50 and 90 values were 4 and 16 µg/mL, respectively, with 74.5% susceptible.
For comparison purposes, Figure 1 is a visual representation of the percent susceptible for all antibiotics within the categories of isolates. For ESBL-producing isolates, the susceptibility rate to tetracycline, amoxicillin-clavulanate, trimethoprim-sulfamethoxazole, nitrofurantoin, and ciprofloxacin varied, ranging from 10.2% to 91.8% for E. coli and 11.6% to 51.2% for K. pneumoniae (Table 1). Omadacycline and nitrofurantoin were the most active agents tested against urinary isolates for both ESBL-producing and non-ESBL-producing E. coli and K. pneumoniae included in this study. Nitrofurantoin performed well against ESBL-producing E. coli and was the only antibiotic that performed better than omadacycline in this category (91.8% vs. 74.5% susceptible, p = 0.001). Compared to ESBL-producing E. coli, the percent susceptible for ESBL-producing K. pneumoniae was lower for all antibiotics tested. Overall, the least active agents against ESBL-producing isolates were trimethoprim-sulfamethoxazole and ciprofloxacin. Omadacycline displayed lower MICs compared to tetracycline regardless of ESBL production. For E. coli isolates, the percent with MIC ≤ 4 µg/mL was 87.3% for omadacycline compared with 47.3% for tetracycline (p < 0.001).
4. Discussion
UTIs affect 150 million patients globally per year and are the leading cause of all infection-related outpatient visits in the United States [14]. Among oral antibiotics, nitrofurantoin and trimethoprim-sulfamethoxazole have been recommended as first-line empiric therapies for acute uncomplicated cystitis [3]. Fluoroquinolones, such as ciprofloxacin, are recommended as alternatives for cystitis due to their broad spectrum of activity and risk for escalating resistance [3]. Resistance within the limited number of oral antibiotic options for UTI is making the choice of therapy complicated.
UTIs caused by Enterobacterales harboring antimicrobial resistance has increased rapidly and can lead to life threating urosepsis. The increasing prevalence of ESBL production among Enterobacterales seriously compromises the activity of many oral antibiotics commonly prescribed for UTI [7]. ESBL-producing Enterobacterales are associated with increased length of hospital stay and mortality [15,16]. Nitrofurantoin remains sufficiently active against ESBL-producing E. coli, but does not provide reliable activity against ESBL-producing K. pneumoniae strains [17], and is not recommended for infections involving upper urinary tract, i.e., pyelonephritis. Furthermore, co-harboring of resistance mechanisms has been observed in ESBL-producing E. coli isolates, further limiting oral antibiotic options [7]. Therefore, new antibiotic options are needed for treating UTIs caused by ESBL-producing Enterobacterales.
Omadacycline as a treatment of UTI has been investigated in two phase 2 studies of uncomplicated cystitis [18] and acute pyelonephritis [19], respectively. In these studies, omadacycline failed to demonstrate non-inferiority versus nitrofurantoin for cystitis and levofloxacin for pyelonephritis. However, different dosing regimens of omadacycline were evaluated in these studies. Results analyzed according to the different dosing regimens suggest the possibility of a dose-response relationship. A trend for increasing rates of clinical success was demonstrated with doses that would result in higher omadacycline exposures. A potential explanation for this effect was described by Pagano and colleagues [20]. Microbiologic activity of omadacycline was shown to be reduced in urine compared with standard culture media. This study also characterized the inhibitory effect that magnesium and calcium may have on the activity of omadacycline. Collectively, these results suggest that relatively aggressive dosing of omadacycline (e.g., 450 mg PO daily) may be necessary to achieve optimal outcomes in treating UTIs, or that omadacycline susceptibility breakpoints for treating UTIs should be lower than what is currently established. Lastly, it is important to note that the phase 2 UTI studies did not specifically evaluate efficacy of omadacycline against ESBL-producing organisms. This represents an opportunity for future research.
Omadacycline has potent in vitro activity against Enterobacterales, including strains that produce ESBL [21,22]. In our study, omadacycline demonstrated in vitro activity against 204 E. coli and K. pneumoniae isolates with 74.5% of isolates having an MIC ≤ 4 µg/mL, the susceptible breakpoint for K. pneumoniae. Pfaller et al. tested omadacycline and comparator agents against Enterobacterales urinary isolates collected in a surveillance program during 2010 and 2014. This study demonstrated that omadacycline was the most active agent tested against E. coli (MIC 50/90, 0.5/2 µg/mL with 99.4% of isolates inhibited at ≤4 µg/mL) and Klebsiella species (MIC 50/90, 2/4 µg/mL with 92.1% of isolates inhibited at ≤4 µg/mL) [23]. However, there was very low proportional representation by ESBL-producing isolates in the study. The percent susceptible in the study by Pfaller and colleagues was higher than that found in our study, for both the overall sample tested and the ESBL-producing isolates. The difference may be due to geographic location of isolates collected, variations in prevalence of ESBL-producing isolates, year of isolation, and microbiologic methodology (broth microdilution versus MIC gradient test strips). When comparing our results to those of other studies, the MIC 50 values of omadacycline against E. coli and K. pneumoniae isolates were marginally higher (4 vs. 1–2 µg/mL) but MIC 90 values were the same (16 µg/mL) [21,24].
Two distinct patterns of omadacycline in vitro activity were observed in our study. Omadacycline exhibited better activity against non-ESBL-producing isolates compared with ESBL-producing isolates. Omadacycline also demonstrated greater in vitro activity against E. coli than K. pneumoniae, including those that were ESBL-producing. Other investigators have also identified these patterns in omadacycline activity [23].
Our study is not without limitations. As this was an in vitro study of bacterial isolates collected in the laboratory, we did not confirm presence of urinary symptoms in the patients whose urine specimens were cultured in the lab, so we are not able to determine whether the isolates represent UTI or asymptomatic bacteriuria. Secondly, the method of susceptibility testing for omadacycline was different than that of the comparator antibiotics. This has the potential to result in slight differences in MICs, although major errors between the methods are not expected. Although the automated phenotypic method used in this study is a validated method to detect ESBL production, we did not perform genetic testing to identify specific ESBL genes in the isolates. However, for surveillance purposes, we have previously performed genetic testing of a collection of isolates within our health system that tested positive for ESBL production by the automated phenotypic method and found that >90% harbor CTX-M genes, the majority of which were CTX-M-15. Lastly, fosfomycin is another oral antibiotic option for UTI. Fosfomycin has microbiologic activity against ESBL-producing Enterobacterales, yet it was not included in the panel of the automated broth microdilution system used in the lab. For that reason, we are not able to make any comparisons between fosfomycin and the antibiotics evaluated in our study.
In conclusion, omadacycline exhibits promising in vitro antimicrobial activity against ESBL-producing E. coli and K. pneumoniae urinary isolates, including those that exhibit resistance to other oral antibiotics used to treat UTI. These data support the investigation of omadacycline as a potential oral option in the treatment of UTI caused by ESBL-producing E. coli and K. pneumoniae. In future studies of UTI, careful consideration should be given to the trial design to account for inhibitory effects of urine and the possibility of a dose-response relationship.
Author Contributions
Conceptualization, T.J.S., E.L.P. and J.C.W.; methodology, T.J.S., A.K., J.C.W. and E.L.P.; validation, A.K. and E.L.P.; formal analysis, T.J.S., A.K. and J.C.W.; investigation, T.J.S., A.K., J.C.W. and E.L.P.; resources, A.K. and E.L.P.; data curation, T.J.S. and A.K.; writing—original draft preparation, A.K. and T.J.S.; writing—review and editing, T.J.S. and J.C.W.; supervision, E.L.P. and J.C.W.; project administration, T.J.S.; funding acquisition, E.L.P. All authors have read and agreed to the published version of the manuscript.
Funding
This study received research support from Paratek Pharmaceuticals, Inc. (award #62669).
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Wake Forest University Health Sciences (IRB00062096, approval 26 February 2020).
Informed Consent Statement
Patient consent was waived due to minimal risk to subjects whose specimens contained the cultured isolates.
Data Availability Statement
The data (MIC results) presented in this study are available on request from the corresponding author.
Conflicts of Interest
E.L.P. received research funding from Paratek Pharmaceuticals, Inc.
References
- Chua, K.P.; Fischer, M.A.; Linder, J.A. Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study. BMJ 2019, 364, k5092. [Google Scholar] [CrossRef] [PubMed]
- Hashimoto, H.; Saito, M.; Sato, J.; Goda, K.; Mitsutake, N.; Kitsuregawa, M.; Nalgai, R.; Hatakeyama, S. Indications and classes of outpatient antibiotic prescriptions in Japan: A descriptive study using the national database of electronic health insurance claims, 2012–2015. Int. J. Infect. Dis. 2020, 91, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Gupta, K.; Hooton, T.M.; Naber, K.G.; Wullt, B.; Colgan, R.; Miller, L.G.; Moran, G.J.; Nicolle, L.E.; Raz, R.; Schaeffer, A.J.; et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 2011, 52, e103–e120. [Google Scholar] [CrossRef] [PubMed]
- Cullen, I.M.; Manecksha, R.P.; McCullagh, E.; Ahmad, S.; O’kelly, F.; Flynn, R.; McDermott, T.E.D.; Murphy, P.; Grainger, R.; Fennell, J.P.; et al. An 11-year analysis of the prevalent uropathogens and the changing pattern of Escherichia coli antibiotic resistance in 38,530 community urinary tract infections, Dublin 1999–2009. Ir. J. Med. Sci. 2013, 182, 81–89. [Google Scholar] [CrossRef] [PubMed]
- Raphael, E.; Glymour, M.M.; Chambers, H.F. Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: Results from 2014 to 2020 in an urban safety-net healthcare system. Antimicrob. Resist. Infect. Control 2021, 10, 118. [Google Scholar] [CrossRef] [PubMed]
- Jernigan, J.A.; Hatfield, K.M.; Wolford, H.; Nelson, R.E.; Olubajo, B.; Reddy, S.C.; McCarthy, N.; Paul, P.; McDonald, L.C.; Kallen, A.; et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017. N. Engl. J. Med. 2020, 382, 1309–1319. [Google Scholar] [CrossRef] [PubMed]
- Critchley, I.A.; Cotroneo, N.; Pucci, M.J.; Jain, A.; Mendes, R.E. Resistance among urinary tract pathogens collected in Europe during 2018. J. Glob. Antimicrob. Resist. 2020, 23, 439–444. [Google Scholar] [CrossRef] [PubMed]
- Kaye, K.S.; Gupta, V.; Mulgirigama, A.; Joshi, A.V.; Scangarella-Oman, N.E.; Yu, K.; Ye, G.; Mitrani-Gold, F.S. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: Rising ESBL strains and impact on patient management. Clin. Infect. Dis. 2021, 73, 1992–1999. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis. Geneva. 2017. Available online: https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12 (accessed on 4 May 2023).
- Macone, A.B.; Caruso, B.K.; Leahy, R.G.; Donatelli, J.; Weir, S.; Draper, M.P.; Tanaka, S.K.; Levy, S.B. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob. Agents Chemother. 2014, 58, 1127–1135. [Google Scholar] [CrossRef] [PubMed]
- Zhanel, G.G.; Esquivel, J.; Zelenitsky, S.; Lawrence, C.K.; Adam, H.J.; Golden, A.; Hink, R.; Berry, L.; Schweizer, F.; Zhanel, M.A.; et al. Omadacycline: A novel oral and intravenous aminomethylcycline antibiotic agent. Drugs 2020, 80, 285–313. [Google Scholar] [CrossRef] [PubMed]
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 30th ed.; CLSI supplement M100; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020. [Google Scholar]
- USFaDARasticfo. Available online: https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria (accessed on 3 April 2020).
- Stamm, W.E.; Norrby, S.R. Urinary tract infections: Disease panorama and challenges. J. Infect. Dis. 2001, 183 (Suppl. S1), S1–S4. [Google Scholar] [CrossRef]
- Raya, G.B.; Dhoubhadel, B.G.; Shrestha, D.; Raya, S.; Laghu, U.; Shah, A.; Raya, B.B.; Kafle, R.; Parry, C.M.; Ariyoshi, K. Multidrug-resistant and extended-spectrum beta-lactamase-producing uropathogens in children in Bhaktapur, Nepal. Trop. Med. Health 2020, 48, 65. [Google Scholar] [CrossRef]
- Critchley, I.A.; Cotroneo, N.; Pucci, M.J.; Mendes, R. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS ONE 2019, 14, e0220265. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.Y.; Lin, H.C.; Lin, Y.C.; Yu, S.-H.; Wu, W.-H.; Lee, Y.-J. Antimicrobial susceptibilities of urinary extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J. Microbiol. Immunol. Infect. 2011, 44, 364–368. [Google Scholar] [CrossRef] [PubMed]
- Overcash, J.S.; Tzanis, E.; Manley, A.; Sirbu, A.; Serio, A.W.; White, T.; Wright, K.; Chitra, S.; Eckburg, P.B. Omadacycline in female adults with cystitis: Results from a randomized, double-blinded, adaptive phase 2 study. In Proceedings of the ID Week 2020, Virtual Event, 21–25 October 2020. [Google Scholar]
- Overcash, J.S.; Tzanis, E.; Manley, A.; Sirbu, A.; Serio, A.W.; White, T.; Wright, K.; Chitra, S.; Eckburg, P.B. Omadacycline in female adults with acute pyelonephritis: Results from a randomized, double-blind, adaptive phase 2 study. In Proceedings of the ID Week 2020, Virtual Event, 21–25 October 2020. [Google Scholar]
- Pagano, P.; Marra, A.; Shinabarger, D.; Pillar, C. In vitro activity of omadacycline and levofloxacin against Escherichia coli, Klebsiella pneumoniae and Staphylococcus saprophyticus in human urine supplemented with calcium and magnesium. J. Antimicrob. Chemother. 2020, 75, 2160–2163. [Google Scholar] [CrossRef] [PubMed]
- Huband, M.D.; Pfaller, M.A.; Shortridge, D.; Flamm, R.K. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017. J. Glob. Antimicrob. Resist. 2019, 19, 56–63. [Google Scholar] [CrossRef]
- Xiao, M.; Huang, J.J.; Zhang, G.; Yang, W.H.; Kong, F.; Kudinha, T.; Xu, Y.C. Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study. BMC Microbiol. 2020, 20, 350. [Google Scholar] [CrossRef] [PubMed]
- Pfaller, M.A.; Rhomberg, P.R.; Huband, M.D.; Flamm, R.K. Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). Diagn. Microbiol. Infect. Dis. 2018, 91, 179–183. [Google Scholar] [CrossRef] [PubMed]
- Pfaller, M.A.; Huband, M.D.; Shortridge, D.; Flamm, R.K. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. Antimicrob. Agents Chemother. 2020, 64, e02488-19. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Percent susceptible of omadacycline and comparator antibiotics.
Table 1.
Activity of omadacycline and comparator antibiotics against E. coli and K. pneumoniae.
| Microorganisms (n a) | Antibiotics | MIC µg/mL | S% | ||||
|---|---|---|---|---|---|---|---|
| MIC50 | MIC90 | Minimum MIC | Maximum MIC | Modal MIC | |||
| All ESBL-producing isolates (102) | Omadacycline | 4 | >32 | 0.25 | >32 | 4 | 54.9 b |
| Tetracycline | >8 | >8 | ≤4 | >8 | >8 | 26.1 | |
| Amoxicillin-clavulanate | 8/4 | 16/8 | ≤4/2 | >16/8 | 16/8 | 51.1 | |
| Trimethoprim-sulfamethoxazole | >2/38 | >2/38 | ≤2/38 | >2/38 | >2/38 | 19.6 | |
| Ciprofloxacin | >2 | >2 | ≤1 | >2 | >2 | 14.1 | |
| Nitrofurantoin | ≤32 | >64 | ≤32 | >64 | ≤32 | 72.8 | |
| All non-ESBL-producing isolates (102) | Omadacycline | 3 | 6 | 0.25 | >32 | 4 | 91.2 b |
| Tetracycline | ≤4 | >8 | ≤4 | >8 | ≤4 | 80.4 | |
| Amoxicillin-clavulanate | ≤4/2 | 16/8 | ≤4/2 | >16/8 | ≤4/2 | 89.2 | |
| Trimethoprim-sulfamethoxazole | ≤2/38 | >2/38 | ≤2/38 | >2/38 | ≤2/38 | 79.4 | |
| Ciprofloxacin | ≤1 | >2 | ≤1 | >2 | ≤1 | 87.3 | |
| Nitrofurantoin | ≤32 | 64 | ≤32 | >64 | ≤32 | 77.5 | |
| ESBL-Producing E. coli (51) | Omadacycline | 4 | 16 | 0.25 | >32 | 4 | 74.5 b |
| Tetracycline | >8 | >8 | ≤4 | >8 | >8 | 26.5 | |
| Amoxicillin-clavulanate | 8/4 | 16/8 | <4/2 | 16/8 | 16/8 | 63.3 | |
| Trimethoprim-sulfamethoxazole | >2/38 | >2/38 | ≤2/38 | >2/38 | >2/38 | 26.5 | |
| Ciprofloxacin | >2 | >2 | ≤1 | >2 | >2 | 10.2 | |
| Nitrofurantoin | ≤32 | ≤32 | ≤32 | >64 | ≤32 | 91.8 | |
| Non-ESBL-Producing E. coli (51) | Omadacycline | 2 | 4 | 1 | 8 | 3 | 100 b |
| Tetracycline | ≤4 | >8 | ≤4 | >8 | ≤4 | 72.6 | |
| Amoxicillin-clavulanate | <4/2 | 16/8 | <4/2 | >16/8 | <4/2 | 86.3 | |
| Trimethoprim-sulfamethoxazole | ≤2/38 | >2/38 | ≤2/38 | >2/38 | ≤2/38 | 78.4 | |
| Ciprofloxacin | ≤1 | >2 | ≤1 | >2 | ≤1 | 82.4 | |
| Nitrofurantoin | ≤32 | ≤32 | ≤32 | >64 | ≤32 | 94.1 | |
| ESBL-Producing K. pneumoniae (51) | Omadacycline | 8 | >32 | 2 | >32 | 4 | 35.3 |
| Tetracycline | ≤4 | >8 | >8 | >8 | >8 | 25.6 | |
| Amoxicillin-clavulanate | <4/2 | >16/8 | <4/2 | >16/8 | 16/8 | 37.2 | |
| Trimethoprim-sulfamethoxazole | ≤2/38 | >2/38 | ≤2/38 | >2/38 | >2/38 | 11.6 | |
| Ciprofloxacin | ≤1 | >2 | ≤1 | >2 | >2 | 18.6 | |
| Nitrofurantoin | ≤32 | >64 | ≤32 | >64 | ≤32 | 51.2 | |
| Non-ESBL-Producing K. pneumoniae (51) | Omadacycline | 4 | 8 | 2 | >32 | 4 | 82.3 |
| Tetracycline | ≤4 | 8 | ≤4 | >8 | ≤4 | 86.3 | |
| Amoxicillin-clavulanate | <4/2 | 8/4 | <4/2 | >16/8 | <4/2 | 92.2 | |
| Trimethoprim-sulfamethoxazole | ≤2/38 | >2/38 | ≤2/38 | >2/38 | ≤2/38 | 80.4 | |
| Ciprofloxacin | ≤1 | >2 | ≤1 | >2 | ≤1 | 92.2 | |
| Nitrofurantoin | <32 | >64 | ≤32 | >64 | ≤32 | 60.8 | |
| All E. coli (102) | Omadacycline | 4 | 8 | 0.25 | >32 | 4 | 87.3 b |
| Tetracycline | ≤4 | >8 | ≤4 | >8 | ≤4 | 47.3 | |
| Amoxicillin-clavulanate | 8/4 | 16/8 | <4/2 | >16/8 | <4/2 | 73.1 | |
| Trimethoprim-sulfamethoxazole | ≤2/38 | >2/38 | ≤2/38 | >2/38 | ≤2/38 | 49.5 | |
| Ciprofloxacin | >2 | >2 | ≤1 | >2 | >2 | 45.2 | |
| Nitrofurantoin | ≤32 | ≤32 | ≤32 | >64 | ≤32 | 92.5 | |
| All K. pneumoniae (102) | Omadacycline | 4 | >32 | 1.5 | >32 | 4 | 61.8 |
| Tetracycline | ≤4 | >8 | ≤4 | >8 | ≤4 | 58.0 | |
| Amoxicillin-clavulanate | <4/2 | >16/8 | <4/2 | >16/8 | <4/2 | 65.9 | |
| Trimethoprim-sulfamethoxazole | >2/38 | >2/38 | ≤2/38 | >2/38 | >2/38 | 45.5 | |
| Ciprofloxacin | ≤1 | >2 | ≤1 | >2 | ≤1 | 55.7 | |
| Nitrofurantoin | ≤32 | >64 | ≤32 | >64 | ≤32 | 55.7 | |
| Total (204) | Omadacycline | 4 | 16 | 0.25 | >32 | 4 | 74.5 b |
| Tetracycline | ≤4 | >8 | ≤4 | >8 | ≤4 | 52.5 | |
| Amoxicillin-clavulanate | 8/4 | 16/8 | <4/2 | >16/8 | <4/2 | 69.6 | |
| Trimethoprim-sulfamethoxazole | ≤2/38 | >2/38 | ≤2/38 | >2/38 | ≤2/38 | 47.5 | |
| Ciprofloxacin | 2 | >2 | ≤1 | >2 | ≤1 | 50.3 | |
| Nitrofurantoin | 64 | >64 | ≤32 | >64 | ≤32 | 74.6 | |
S, susceptible; ESBL, extended spectrum β-lactamase. a Stated n represents number of isolates tested against omadacycline. Comparator antibiotic MIC results were not available for 23 isolates (n = 181 for comparator antibiotics). b Breakpoint of K. pneumoniae (≤4 µg/mL) was used for interpreting E. coli susceptibility.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Stone, T.J.; Kilic, A.; Williamson, J.C.; Palavecino, E.L. In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates. Antibiotics 2023, 12, 953. https://doi.org/10.3390/antibiotics12060953
AMA Style
Stone TJ, Kilic A, Williamson JC, Palavecino EL. In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates. Antibiotics. 2023; 12(6):953. https://doi.org/10.3390/antibiotics12060953
Chicago/Turabian StyleStone, Tyler J., Abdullah Kilic, John C. Williamson, and Elizabeth L. Palavecino. 2023. "In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates" Antibiotics 12, no. 6: 953. https://doi.org/10.3390/antibiotics12060953
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
